New York, NYNCT05592015Now EnrollingIRB Ready

T-Cell Large Granular Lymphocytic Leukemia Clinical Trial in New York, NY

Access cutting-edge t-cell large granular lymphocytic leukemia treatment through this clinical trial at a research site in New York. Study-provided care at no cost to qualified participants.

Sponsored by Jonathan Brammer

Quick Self-Assessment

See if you qualify for this New York location

Preparing your pre-screening questions...

Expert Care in New York

Access t-cell large granular lymphocytic leukemia specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related t-cell large granular lymphocytic leukemia treatment provided free

Apply for This New York Location

Check if you qualify for this t-cell large granular lymphocytic leukemia clinical trial in New York, NY

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to New York

    Convenient for NY residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit New York site if eligible
  4. 4Begin participation

About This T-Cell Large Granular Lymphocytic Leukemia Study in New York

This phase II trial tests whether ruxolitinib works to shrink tumors in patients with T-cell large granular lymphocyte leukemia. Ruxolitinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

Sponsor: Jonathan Brammer

Who Can Participate

Inclusion Criteria

Age 18 or older and able to swallow pills
Diagnosis of T-LGLL defined as: CD3+CD8+ cell population \> 650/mm\^3 or CD3+CD8+CD57+ population \> 500/mm\^3 and the presence of a clonal T-cell receptor (within 1 month of diagnosis). Note: patients with MDS-like T-LGLL may be included with PI approval even if CD3+CD8+ cell population is \< 650/mm\^3, though +TCR is required. Natural-Killer (NK) LGL is also permitted, provided there is a clonal NK-cell population noted with \> 500 cells/mm\^3
Untreated T-LGLL or failed at least one line of frontline therapy;
Patients must be off treatment for at least 14 days or 5 half-lives, whichever is longer
Require Treatment for T-LGLL (one or more required)
Symptomatic anemia with hemoglobin \< 10 g/dL
Transfusion-dependent anemia
Neutropenia with absolute neutrophil count (ANC) \< 500/mm\^3
Neutropenia with ANC \< 1500/mm\^3 with recurrent infections
Platelet count \> 50 x 10\^9/L. Platelet transfusion

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in New York?

Yes, this clinical trial (NCT05592015) has an active research site in New York, NY that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

T-Cell Large Granular Lymphocytic Leukemia Treatment Options in New York, NY

If you're searching for t-cell large granular lymphocytic leukemia treatment options in New York, NY, this clinical trial (NCT05592015) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our New York research site is actively enrolling participants for this clinical trial. You'll receive care from experienced t-cell large granular lymphocytic leukemia specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all t-cell large granular lymphocytic leukemia clinical trials near you to find additional studies recruiting in your area.

More Leukemia Trials in New York, NY

See all leukemia clinical trials recruiting in New York — not just this study.

Browse Leukemia Trials in New York →

Browse More Trials by Condition

Leukemia TrialsHeart Attack TrialsRheumatoid Arthritis TrialsPulmonary Hypertension TrialsInterstitial Cystitis TrialsMyocardial Infarction TrialsAll Conditions →

Ready to Join in New York?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · New York, NY